Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


France Warns Diabetics And Others Against Using Joint Health Supplements

Executive Summary

Diabetics, pregnant women, children, and those with certain food allergies in France should stop taking joint health supplements containing glucosamine and/or chondroitin sulfate due to a risk of adverse events, says national food regulator ANSES. Local supplements industry association Synadiet has insisted the products are safe and cases of adverse reactions rare.

You may also be interested in...

Glucosamine Supps For Heart Health? Large UK Biobank Study Says Yes

A large-population UK study published in the British Medical Journal has found that habitual use of glucosamine supplements may reduce the risk of cardiovascular disease events, such as 

MHRA set to reclassify glucosamine supplements

High-strength glucosamine food supplements sold in the UK will now be classified as medicines and require a marketing authorisation after the country’s Medicines and Healthcare products Regulatory Agency (MHRA) introduced tighter regulations for such products.

Recordati’s OTC Sales Lifted by Acquisitions And Italy

Italy's Recordati enjoyed strong growth in its home market and abroad, lifting OTC group sales in 2019.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts